MedTrace Logo

Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)

NCT00095069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2015-01-14

No results posted yet for this study

Summary

The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.

Conditions

Interventions

DRUG

MK0928, gaboxadol / Duration of Treatment - 1 year

DRUG

Comparator: placebo / Duration of Treatment -1 year

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095069 on ClinicalTrials.gov